Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shining a light on brain energy: a new window into bipolar depression

NCT ID NCT07806227

Knowledge-focused Sponsor: Martin Lan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

Researchers are testing whether a light-based imaging technique called near-infrared spectroscopy can measure mitochondrial activity in the brain during bipolar depression. People with bipolar disorder who are depressed will undergo brain imaging before and after treatment with the approved medication lurasidone, and will also provide blood samples and answer questions about their history. Healthy volunteers without any psychiatric disorder will have the same imaging and questionnaires, but will not take the medication. The goal is to understand how mitochondrial function relates to depression symptoms and whether it changes with treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lurasidone (Latuda), an approved medication for bipolar depression, used to see how brain imaging signals change as symptoms improve.
What this could lead to
If this works, it could point toward a way to measure mitochondrial function in the brain, helping to guide depression treatment and deepen understanding of bipolar disorder.
What could go wrong
This is a small, early-stage imaging study, not a treatment trial. The results may not lead to a new therapy, and the imaging technique may not reliably reflect mitochondrial activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of bipolar disorder * Having symptoms of depression * Taking less than three medications for bipolar disorder Exclusion Criteria: * Taking any medications that cannot be combined with lurasidone * Any medical problems that are not well treated * Any drug or alcohol use disorders that are moderate or severe * Any severe suicidal ideation, or having had a suicide attempt in the last five years * Any psychotic symptoms that have occurred outside of a mood episode * Any electroconvulsive therapy (ECT) within the last six months * Currently pregnant or planning to become pregnant during the time of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder depression are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar depression bipolar disorder Depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar disorder depression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • New York State Psychiatric Institute

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.